Trial intelligence / Profile preview

SIOP Ependymoma II Program

2024-512222-28-00Phase 3Authorised

Sponsor: Centre Léon Bérard
Start: Nov 2024
Modality: Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Countries: 15

Overview

Phase 3 trial of etoposide, cisplatin, methotrexate, vincristine, valproic acid and 1 more in ependymoma (3 arms), sponsored by Centre Léon Bérard. Primary endpoints: Gross Total Resection (GTR) rate, Progression-Free Survival (PFS) - Stratum 1 and 2 more. Planned start Nov 2024; status: authorised.

Drugs

etoposidecisplatinmethotrexatevincristinevalproic acid

Conditions

ependymoma

Beyond the preview

Go deeper on 2024-512222-28-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2024-512222-28-00.